These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 21778401)

  • 1. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.
    Wu CC; Li TK; Farh L; Lin LY; Lin TS; Yu YJ; Yen TJ; Chiang CW; Chan NL
    Science; 2011 Jul; 333(6041):459-62. PubMed ID: 21778401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insight into eukaryotic topoisomerase II-inhibiting fused heterocyclic compounds in human cancer cell lines by molecular docking.
    Taskin T; Yilmaz S; Yildiz I; Yalcin I; Aki E
    SAR QSAR Environ Res; 2012; 23(3-4):345-55. PubMed ID: 22490049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance.
    Kingma PS; Burden DA; Osheroff N
    Biochemistry; 1999 Mar; 38(12):3457-61. PubMed ID: 10090731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catalytic core of human topoisomerase IIα: insights into enzyme-DNA interactions and drug mechanism.
    Lindsey RH; Pendleton M; Ashley RE; Mercer SL; Deweese JE; Osheroff N
    Biochemistry; 2014 Oct; 53(41):6595-602. PubMed ID: 25280269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs.
    Wu CC; Li YC; Wang YR; Li TK; Chan NL
    Nucleic Acids Res; 2013 Dec; 41(22):10630-40. PubMed ID: 24038465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs.
    Chen W; Qiu J; Shen YM
    Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Random mutagenesis of the B'A' core domain of yeast DNA topoisomerase II and large-scale screens of mutants resistant to the anticancer drug etoposide.
    Jiang X
    Biochem Biophys Res Commun; 2005 Feb; 327(2):597-603. PubMed ID: 15629155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthracenedione-methionine conjugates are novel topoisomerase II-targeting anticancer agents with favorable drug resistance profiles.
    Lee CH; Hsieh MY; Hsin LW; Chen HC; Lo SC; Fan JR; Chen WR; Chen HW; Chan NL; Li TK
    Biochem Pharmacol; 2012 May; 83(9):1208-16. PubMed ID: 22306066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase.
    Baviskar AT; Madaan C; Preet R; Mohapatra P; Jain V; Agarwal A; Guchhait SK; Kundu CN; Banerjee UC; Bharatam PV
    J Med Chem; 2011 Jul; 54(14):5013-30. PubMed ID: 21644529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction model for anthracycline activity against DNA topoisomerase II.
    Moro S; Beretta GL; Dal Ben D; Nitiss J; Palumbo M; Capranico G
    Biochemistry; 2004 Jun; 43(23):7503-13. PubMed ID: 15182192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the topoisomerase II-DNA cleavable complex by the ortho-quinone derivative of the antitumor drug etoposide (VP-16).
    Gantchev TG; Hunting DJ
    Biochem Biophys Res Commun; 1997 Aug; 237(1):24-7. PubMed ID: 9266822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation P732L in human DNA topoisomerase IIbeta abolishes DNA cleavage in the presence of calcium and confers drug resistance.
    Leontiou C; Lakey JH; Lightowlers R; Turnbull RM; Austin CA
    Mol Pharmacol; 2006 Jan; 69(1):130-9. PubMed ID: 16239602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation of cysteine residue 455 to alanine in human topoisomerase IIalpha confers hypersensitivity to quinones: enhancing DNA scission by closing the N-terminal protein gate.
    Bender RP; Osheroff N
    Chem Res Toxicol; 2007 Jun; 20(6):975-81. PubMed ID: 17516663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of friedelan triterpenoid analogs with DNA topoisomerase IIα inhibitory activity and their molecular docking studies.
    Mandal A; Ghosh S; Bothra AK; Nanda AK; Ghosh P
    Eur J Med Chem; 2012 Aug; 54():137-43. PubMed ID: 22633831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.
    Liu YX; Hsiung Y; Jannatipour M; Yeh Y; Nitiss JL
    Cancer Res; 1994 Jun; 54(11):2943-51. PubMed ID: 8187080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine.
    Cline SD; Macdonald TL; Osheroff N
    Biochemistry; 1997 Oct; 36(42):13095-101. PubMed ID: 9335572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
    Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.